罗斯术后肺动脉同种移植物失功的经导管与外科瓣膜置换比较
回顾性分析本机构47例经导管肺动脉瓣置换与41例外科肺动脉瓣置换的罗斯术后患者,两组手术死亡率均低,6年无事件生存率与肺动脉瓣再干预率无显著差异,但经导管组肺动脉瓣相关感染性心内膜炎更常见(13% vs 0%,P=.04)。
要点
- 经导管与外科肺动脉瓣置换术后6年无事件生存率无显著差异(79%±7% vs 91%±4%,P=.15)。
- 经导管组肺动脉瓣相关感染性心内膜炎显著更常见(13% vs 0%,P=.04),年化率2.98%/患者年。
- 外科组瓣膜功能障碍有增多趋势(67%±8% vs 35%±8%,P=.08),但未达统计学显著。
核心结论
- 罗斯术后需肺动脉同种移植物再干预的患者中,经导管与外科肺动脉瓣置换均提供低手术死亡率和相当的中期结局,死亡率或肺动脉瓣再干预无显著差异,但经导管术后感染性心内膜炎更常见,需更大样本随机研究确定各术式在患者管理中的作用。
研究设计与样本
- 回顾性分析本机构年龄≥14岁、接受经导管肺动脉瓣置换(n=47)或外科肺动脉瓣置换(n=41)的罗斯术后患者,复习临床与超声心动图数据。
主要发现
- 两组基线和左、右心室收缩功能相似;经导管组平均随访56±24个月,外科组89±46个月(P<.001)。
- 两组均无手术相关死亡;6年随访无事件生存率经导管组79%±7% vs 外科组91%±4%(P=.15),肺动脉瓣再干预率经导管组26%±9% vs 外科组8%±5%(P=.31)。
- 肺动脉瓣相关感染性心内膜炎经导管组13% vs 外科组0%(P=.04),年化率2.98%/患者年。
- 外科组瓣膜功能障碍有增多趋势(67%±8% vs 经导管组35%±8%,P=.08)。
临床怎么用
- 作者结论指出,罗斯术后肺动脉同种移植物再干预时经导管与外科肺动脉瓣置换均提供低手术死亡率和相当的中期结局,但经导管术后感染性心内膜炎更常见,需更大样本随机研究确定各术式作用。
局限性
- 原文结论指出需更大样本随机研究确定各术式在患者管理中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients who undergo the Ross procedure are at increased risk of pulmonary valve (PV) homograft dysfunction. For those who require reintervention on the homograft, transcatheter PV replacement (tPVR) provides a less invasive therapeutic option than surgical PVR (sPVR). We examined the outcomes following tPVR versus sPVR in a cohort of patients who underwent the Ross procedure. METHODS: We performed a retrospective analysis of Ross patients age ≥14 years who underwent tPVR (n = 47) or sPVR (n = 41) at our institution. The patients' clinical and echocardiographic data were reviewed. RESULTS: Baseline parameters, including demographic data and left ventricular and right ventricular (RV) systolic function, were similar in the 2 groups. The mean follow-up was 56 ± 24 months for the tPVR group and 89 ± 46 months for the sPVR group (P < .001). No procedure-related mortality was noted in either group. At 6-year follow-up, there was no significant between-group difference in event-free survival (tPVR, 79% ± 7% vs sPVR, 91% ± 4%; P = .15) or PV reintervention (tPVR, 26% ± 9% vs sPVR, 8% ± 5%; P = .31). PV-associated infective endocarditis (IE) was significantly more common with tPVR (tPVR, 13% vs sPVR, 0%; P = .04), with an annualized rate of 2.98% per patient-year. In addition, there was a trend toward more valve dysfunction following sPVR (sPVR, 67% ± 8% vs tPVR, 35% ± 8%; P = .08). CONCLUSIONS: In Ross patients who require reintervention on the PV homograft, both tPVR and sPVR provide low procedural mortality and comparable midterm outcome with no significant difference in mortality or PV reintervention. However, IE is more common following tPVR. A larger randomized study is needed to determine the role of each procedure in patient management.
引用
- Alassas K, Mohty D, Clavel MA, et al. Transcatheter versus surgical valve replacement for a failed pulmonary homograft in the Ross population. J Thorac Cardiovasc Surg. 2017. PMID: 29395212. doi:10.1016/j.jtcvs.2017.10.141
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。